1. A wearable device perspective on the standard definitions of disability progression in multiple sclerosis;Dalla Costa;Mult. Scler.,2023
2. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II;Gärtner;Mult. Scler.,2022
3. Schrimpf, G. (2023, December 5). Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis. https://www.merckgroup.com. Retrieved December 10, 2023, from https://www.merckgroup.com/en/news/evobrutinib-phase-lll.html.
4. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis;Yong;Nat. Rev. Neurol.,2022